02.02. Área de Salud II Cartagena

Infliximab-Induced Pneumonitis in a Patient With Sarcoidosis: A Case Report.

Wed, 01 Apr 2026 00:00:00 GMT

Infliximab-Induced Pneumonitis in a Patient With Sarcoidosis: A Case Report. Jiménez-Romero, Alexander-Ali; Guillamón-Sánchez, Mercedes; Velasco-Alcázar, Maria-del-Carmen; Serrano-Cortés, Cristina Infliximab, a tumor necrosis factor alpha (TNF-?) inhibitor, is recommended in selected cases of pulmonary sarcoidosis. Although infectious complications are well recognized, non-infectious pulmonary toxicity is less frequently reported. We describe the case of a 52-year-old woman with atypical alveolar sarcoidosis who developed acute pneumonitis after initiation of infliximab. The patient had persistent disease despite treatment with systemic corticosteroids and methotrexate and was started on infliximab. Following the second dose, she presented with acute worsening dyspnea, tachycardia, and desaturation. High-resolution computed tomography revealed bilateral mosaic attenuation and ground-glass nodules. An infectious cause was excluded, and the temporal relationship with infliximab exposure supported the diagnosis of infliximab-induced pneumonitis. Treatment with high-dose systemic corticosteroids led to clinical and radiological improvement, and infliximab was permanently discontinued. To our knowledge, this is the first reported case of infliximab-induced pneumonitis in the specific setting of pulmonary sarcoidosis.

Reference Equations for Maximal Respiratory Pressures in Healthy Children and Adolescents

Sun, 01 Mar 2026 00:00:00 GMT

Reference Equations for Maximal Respiratory Pressures in Healthy Children and Adolescents Barral-Fernández, Margarita; Jacome-Pumar, María-Amalia; Souto-Camba, Sonia; González-Doniz, Luz; Belmonte, María-Antonia-Ramon; Amor-Barbosa, Marta; Arbillaga-Etxarri, Ane; Mazzucco, Guillermo; Bravo-Cortés, Pilar; del-Corral, Tamara; Martín-Valero, Rocío; Llorca-Cerdá, Carlos; Murcia-Lillo, Fabiola; Sánchez-Santos, José-Antonio; Francin-Gallego, Marina; Martín-Cortijo, Concepción; García-Delgado, Esther; Serrano-Veguillas, Cristina; Varas-de-La-Fuente, Ana-B; San-José-Herranz, Paula; González-Montanez, Carolina; Gimeno-Santos, Elena; Torres-Castro, Rodrigo; Fregonezi, Guilherme-A.-F; Pardas-Peraferrer, Mireia; Vilaró-Casamitjana, Jordi; Fernández-Cadenas, Ángeles; Ríos-Cortes, Antonio-T; Moreno-Valera, María-José; Langer, Daniel; Lista-Paz, Ana OBJECTIVES: Maximal respiratory pressures are key indicators of respiratory muscle strength; however, reference equations and cut-offs to define respiratory muscle weakness are scarce in the European paediatric population. The aim was to create sex-specific reference equations for maximal inspiratory and expiratory pressures (PImax/PEmax) in a large sample of healthy children and to objectively establish cut-offs to define respiratory muscle weakness. METHODS: A multicentre cross-sectional study was conducted across 14 Spanish centres. Healthy children aged 6-18 years, stratified by sex and age, were recruited. Maximal respiratory pressures were measured following standardized methodology in accordance with international guidelines. Reference equations were developed through multiple linear regression analyses. Age- and sex specific cut-offs for respiratory muscle weakness were determined using Z-scores?1.645 standard deviation (SD) below group means. RESULTS: The final sample included 513 subjects (257 boys; 11.5 [SD3.5] years). Reference equations are: (1) PImax: boys=-41.41+10.21age+6.26body mass index (BMI)-0.37ageBMI; girls=125.96-0.34age-0.41age(2)-5.75BMI+0.63ageBMI; (2) PEmax: boys=20.93+5.23age+2.93BMI; girls=-12.67+11.98age-0.39age(2)+2.57BMI. Cut-offs for respiratory muscle weakness are higher in boys and increase with age (p<.001). Depending on age, PImax cut-offs range from 46 to 85cmH(2)O in boys and from 45 to 68cmH(2)O in girls, while PEmax cut-offs span 54-98cmH(2)O in boys and 57-85cmH(2)O in girls. CONCLUSIONS: This study provides new reference equations for PImax and PEmax derived from the largest dataset of normative values in European children and adolescents. It also establishes age-specific cut-offs to define respiratory muscle weakness. These findings will facilitate the identification of respiratory muscle weakness and the selection of candidates for targeted training programmes.

Can Peer Victimization Invalidate the Positive Effect of Emotional Intelligence on Adolescents' Health-Related Quality of Life?

Wed, 01 Apr 2026 00:00:00 GMT

Can Peer Victimization Invalidate the Positive Effect of Emotional Intelligence on Adolescents' Health-Related Quality of Life? de-Lourdes-Martin-Pérez, Ángela; Gascón-Cánovas, Juan-José BACKGROUND: Emotional intelligence (EI) is a key factor in adolescents' health-related quality of life (HRQoL). Previous research has shown that higher EI is associated with better HRQoL outcomes. However, its protective role may be weakened by adverse experiences such as peer victimization. This study examined whether forms of peer victimization moderate the relationship between EI and specific HRQoL dimensions. METHODS: A total of 1427 Spanish adolescents completed a survey-based assessment, including validated measures of victimization (APRI-Bullying), HRQoL (KIDSCREEN-52), and EI (TMMS-24). Moderation effects were tested using multivariate linear regression and the PROCESS macro in SPSS. RESULTS: Verbal victimization moderated the associations between all EI dimensions and the "Social Support and Peers" HRQoL dimension. Social victimization moderated the relationships of "Attention" and "Clarity" with this dimension, whereas physical violence moderated the association between "Repair" and this dimension. No moderating effects were found for Psychological Well-being. IMPLICATIONS FOR SCHOOL HEALTH POLICY, PRACTICE, AND EQUITY: School-based EI programs may enhance adolescents' coping with peer victimization and help protect HRQoL in victimized adolescents. CONCLUSIONS: The positive association between EI and the HRQoL dimension related to perceived social support could disappear in adolescents exposed to moderate or high levels of peer victimization.

Undiagnosed chronic kidney disease in people with type 2 diabetes in Spain: Prevalence, treatment patterns and associated factors in a multicentre cross-sectional study.

Sun, 01 Feb 2026 00:00:00 GMT

Undiagnosed chronic kidney disease in people with type 2 diabetes in Spain: Prevalence, treatment patterns and associated factors in a multicentre cross-sectional study. Cebrian-Cuenca, A; Cornejo-Martin, J; Álvarez-Guisasola, F; Orozco-Beltran, D; Quesada, JA; Artola-Menendez, S; Mata-Cases, M; Pérez-Pérez, A BACKGROUND AND AIM: Chronic kidney disease (CKD) remains underdiagnosed in people with type 2 diabetes mellitus (T2DM), particularly in early stages, despite its strong association with renal disease progression, cardiovascular outcomes, and current guideline recommendations for early cardio-renal protective interventions. Contemporary, nationally representative primary care data from Spain evaluating CKD underdiagnosis in people with T2DM are limited. This study estimated the prevalence of diagnosed and undiagnosed CKD in adults with T2DM in Spain, described treatment patterns by CKD diagnosis status, and identified factors associated with undiagnosed CKD. METHODS: A planned secondary analysis of the DIAMOND2 multicentre cross-sectional study was performed in Spanish primary care. Data were retrospectively collected from electronic medical records during the calendar year 2022, and the analysis was performed between January and July 2023. Data from 5009 adults with T2DM randomly selected from 70 centres were analysed. CKD was defined according to KDIGO 2024 criteria as estimated glomerular filtration rate (eGFR)